DMTK.Q Stock Overview
A molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DermTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.09 |
| 52 Week High | US$3.90 |
| 52 Week Low | US$0.06 |
| Beta | 2.42 |
| 11 Month Change | -71.46% |
| 3 Month Change | -86.76% |
| 1 Year Change | -96.86% |
| 33 Year Change | -99.76% |
| 5 Year Change | n/a |
| Change since IPO | -98.36% |
Recent News & Updates
Recent updates
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%
May 21
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02Shareholder Returns
| DMTK.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.1% | -1.9% | 0.5% |
| 1Y | -96.9% | 10.4% | 20.5% |
Return vs Industry: DMTK.Q underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: DMTK.Q underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| DMTK.Q volatility | |
|---|---|
| DMTK.Q Average Weekly Movement | 22.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DMTK.Q's share price has been volatile over the past 3 months.
Volatility Over Time: DMTK.Q's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 207 | Bret Christensen | www.dermtech.com |
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.
DermTech, Inc. Fundamentals Summary
| DMTK.Q fundamental statistics | |
|---|---|
| Market cap | US$3.58m |
| Earnings (TTM) | -US$89.63m |
| Revenue (TTM) | US$15.66m |
0.2x
P/S Ratio0.0x
P/E RatioIs DMTK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMTK.Q income statement (TTM) | |
|---|---|
| Revenue | US$15.66m |
| Cost of Revenue | US$14.33m |
| Gross Profit | US$1.33m |
| Other Expenses | US$90.96m |
| Earnings | -US$89.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.56 |
| Gross Margin | 8.51% |
| Net Profit Margin | -572.19% |
| Debt/Equity Ratio | 0% |
How did DMTK.Q perform over the long term?
See historical performance and comparison